Solventum Corporation $SOLV Shares Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. lifted its position in shares of Solventum Corporation (NYSE:SOLV) by 72.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,646 shares of the company’s stock after buying an additional 7,821 shares during the period. Fox Run Management L.L.C.’s holdings in Solventum were worth $1,478,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in SOLV. Hilltop National Bank increased its holdings in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in Solventum in the 3rd quarter valued at $25,000. JNBA Financial Advisors increased its holdings in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new stake in Solventum in the 2nd quarter valued at $28,000. Finally, City State Bank increased its holdings in Solventum by 166.7% in the 4th quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after purchasing an additional 240 shares in the last quarter.

Solventum Stock Performance

Shares of SOLV stock opened at $78.70 on Tuesday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20. The company’s 50-day simple moving average is $71.19 and its 200-day simple moving average is $75.21. The stock has a market capitalization of $13.63 billion, a price-to-earnings ratio of 9.64, a PEG ratio of 1.25 and a beta of 0.69.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the company posted $1.34 earnings per share. The company’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Rothschild & Co Redburn assumed coverage on Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target for the company. Wedbush assumed coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target for the company. Piper Sandler lowered their price target on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. KeyCorp increased their price target on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, BTIG Research reiterated a “buy” rating and issued a $89.00 price target on shares of Solventum in a report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $84.25.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.